Description: Does Cardinal Health (CAH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Description: The average brokerage recommendation (ABR) for Cardinal (CAH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Description: Curious if Cardinal Health is trading at a bargain or getting ahead of itself? Let's get right to what matters for anyone eyeing long-term value. With shares up 3.3% in the last week and a stunning 81.1% year-to-date, Cardinal Health is catching the attention of growth hunters and value seekers alike. Recent news of major contract wins and partnerships in the healthcare supply chain have fueled optimism, suggesting Cardinal Health is strengthening its role in the industry. These developments...

Description: Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.

Description: Cardinal (CAH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Description: Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Description: Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Description: Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Description: Dividend growers like NTES and LRCX emerge as defensive standouts as Wall Street rebounds and investors seek stability amid market uncertainty.

Description: Cardinal Health (CAH) shares jumped after the company reported a Q3 earnings beat, delivering revenue and earnings above expectations. EPS rose more than 16% above consensus, sparking renewed optimism among investors. See our latest analysis for Cardinal Health. After its latest earnings beat, Cardinal Health is enjoying a powerful run, with a 31.3% jump in share price over the past month and a remarkable 77.5% year-to-date share price return. Recent momentum is fueled by upbeat quarterly...

Description: Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

Description: CVS Health's Aetna debuts an embedded generative AI assistant designed to simplify benefits navigation and elevate the consumer health experience.

Description: These three top-performing stocks have been quietly reaching new highs.

Description: OnPoint Surgical, Inc., a leader in Augmented Reality (AR) and Artificial Intelligence (AI) guidance for spinal interventions, today announced the appointment of Jeremy Laynor as Chief Commercial Officer (CCO).

Description: There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'll want to see a...

Description: As Wall Street rebounds on hopes of a shutdown resolution, investors turn to value picks like LTH, CAH, MCK and FLS with strong interest coverage ratios.

Description: Does Cardinal Health (CAH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Description: The Biopsy Devices market is projected to reach $4.02 billion by 2033, growing from $2.43 billion in 2024 at a CAGR of 5.75%. This growth is driven by personalized care demand, rising cancer cases, and minimally invasive treatments enhancing patient comfort. Key biopsy devices include needle, punch, and surgical tools for various medical needs. Advancements in biopsy technology ensure precise, early cancer detection and improved patient outcomes. Leading companies like Cardinal Health, Hologic,

Description: Cardinal Health (CAH) shares have climbed over the past month, gaining nearly 29% and catching the eye of many investors. Strong and consistent earnings, along with steady revenue growth, are keeping momentum going for this healthcare distributor. See our latest analysis for Cardinal Health. After a stellar rally in recent weeks, Cardinal Health’s share price has surged to $203.67, pushing its year-to-date share price return to an impressive 72.57%. That momentum follows steady execution and...

Description: It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Description: Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Description: According to the average brokerage recommendation (ABR), one should invest in Cardinal (CAH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Description: Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.

Description: Here is how Alkermes (ALKS) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Description: Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Description: Cardinal Health has experienced robust growth in earnings and topline recently. Observing the momentum, analysts remain strongly bullish on the stock’s prospects.

Description: Cardinal Health’s third quarter performance prompted a positive market reaction, as the company delivered broad-based growth across all five operating segments. Management pointed to robust demand in its Pharmaceutical and Specialty Solutions segment, supported by new customer wins and continued strength in specialty pharmaceuticals, generics, and consumer health. CEO Jason Hollar highlighted meaningful contributions from the company’s MSO (Management Services Organization) platforms and bio-pha

Description: From AI-fueled AppLovin stock to a barrage of defense leaders, the IBD Breakout Stocks Index puts a wide range of names in focus.

Description: Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on January 15, 2026 to shareholders of record at the close of business on January 2, 2026.

Description: Key Insights Significantly high institutional ownership implies Cardinal Health's stock price is sensitive to their...

Description: While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

Description: Cardinal Health (NYSE: CAH) announced today that it has completed its acquisition of Solaris Health, the country's leading urology MSO. Solaris Health brings more than 750 providers across more than 250 practice locations in 14 states and adds immediate scale to the Urology Alliance within Cardinal Health's leading multi-specialty MSO platform, The Specialty Alliance.

Description: We recently published 10 Stocks on Jim Cramer’s Radar. Cardinal Health, Inc. (NYSE:CAH) is one of the stocks Jim Cramer recently discussed. In a show where Cramer spent most of the time discussing Meta and cloud computing, healthcare products and services provider Cardinal Health, Inc. (NYSE:CAH) was a nice shift. Even though the CNBC TV […]

Description: Cardinal Health’s Fair Value Estimate has seen a moderate uplift, increasing from $180.46 to $189.36 per share as a result of shifting analyst views. This change follows strong quarterly performance and new operational guidance, which reinforces optimism in the company’s growth prospects while also highlighting areas for careful observation. Stay tuned to learn how you can remain informed as Cardinal Health’s evolving narrative continues to shape price target updates. Stay updated as the Fair...

Description: Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.

Description: Healthcare distributor and services company Cardinal Health (NYSE:CAH) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 22.4% year on year to $64.01 billion. Its non-GAAP profit of $2.55 per share was 17.3% above analysts’ consensus estimates.

Description: We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Cardinal Health Inc. (NYSE:CAH) is one of the best-performing stocks on Thursday. Cardinal Health propelled to a new 52-week high on Thursday, as investors snapped up shares after posting an impressive earnings performance and raising its growth outlook for fiscal year 2026. At […]

Description: Companies in The News Are: WDC,LLY,IP,CAH

Description: Check out the companies making headlines this week:

Description: Investors were hoping that the company's inaugural earnings release for fiscal 2026 is a harbinger of a prosperous year.

Description: Cardinal Health Inc (CAH) reports strong double-digit growth across all segments, raises full-year EPS guidance, and anticipates continued momentum despite external challenges.

Description: S&P 500 stocks Cardinal Health and C.H. Robinson both had breakouts Thursday after reporting third-quarter earnings. Meanwhile, fellow S&P 500 component Chipotle sank after earnings, receiving several price target cuts.

Description: Shares of healthcare distributor Cencora (NYSE:COR) jumped 3.3% in the morning session after Mizuho analyst Steven Valiquette raised the price target on the company's shares. The price target was increased to $340 from $334, while the firm kept an 'Outperform' rating on the stock. This move signaled continued confidence in Cencora's market performance. Adding to the positive mood in the sector, a key peer, Cardinal Health, reported strong quarterly results and lifted its outlook for the year. Ca

Description: Shares of healthcare distributor and services company Cardinal Health (NYSE:CAH) jumped 16.5% in the morning session after the company reported strong third-quarter 2025 earnings that beat expectations and raised its full-year guidance.

Description: Cardinal Health is charting the next chapter in pharmaceutical logistics with a major investment in modernizing and expanding its distribution network. Designed to improve efficiency, enhance customer responsiveness, and create safer, more supportive workplaces, these upgrades signal a new era in how pharmaceuticals and wellness products move through the supply chain. At the center of […] The post Cardinal Health brings modernization and automation to the pharmaceutical supply chain appeared fir

Description: Cardinal Health (CAH) stock is climbing to a new record high after the company reported earnings results that beat on the top and bottom lines. Cardinal Health CFO Aaron Alt joins Market Catalysts to discuss the earnings print and the company's strategy for future growth. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Pharmaceutical distributor Cardinal Health posted a strong fiscal first quarter and raised its full-year outlook on Thursday, causing shares to surge toward their highest closing level on record. For fiscal 2026, Cardinal Health expects adjusted earnings in the range of $9.65 to $9.85 a share. Analysts polled by FactSet were looking for $9.44.

Description: Cardinal Health (NYSE: CAH) delivered a commanding first quarter for fiscal 2026, beating both earnings and revenue expectations by wide margins while raising full-year guidance. The stock climbed 1% in early trading as investors digested results that extend a perfect eight-quarter beat streak. A Quarter of Broad Execution Non-GAAP earnings per share came in at ... Cardinal Health Surges After Reporting Strong Q1 Financial Results

Description: Cardinal Health delivered a strong Q1 beat and lifted its 2026 EPS outlook, fueled by broad-based growth and rising profits across all business segments.

Description: While the top- and bottom-line numbers for Cardinal (CAH) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: Cardinal (CAH) delivered earnings and revenue surprises of +15.38% and +8.39%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Healthcare distributor and services company Cardinal Health (NYSE:CAH) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 22.4% year on year to $64.01 billion. Its non-GAAP profit of $2.55 per share was 17.3% above analysts’ consensus estimates.

Description: The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $2.21 per share. The prescription drug distributor posted revenue of $64.01 billion in the period, which also beat Street forecasts.

Description: Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2026 revenues of $64 billion, an increase of 22% from the first quarter of fiscal year 2025. First quarter GAAP operating earnings increased 18% to $668 million and GAAP diluted earnings per share (EPS) increased 11% to $1.88. First quarter non-GAAP operating earnings increased 37% to $857 million, driven by segment profit growth across all five of the company's operating segments. Non-GAAP diluted EPS increased 36% to $2.55, r

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: In the past week, Cardinal Health announced it will report its Q3 earnings, with analysts projecting a sizable revenue increase to US$59.36 billion and adjusted earnings of US$2.17 per share, reversing a decline in the prior year quarter. An interesting insight is that Cardinal Health's role in specialized healthcare logistics, such as cell and gene therapy distribution, is gaining prominence as the industry shifts toward advanced therapies and complex supply chains. To assess the...

Description: Many Cardinal Health, Inc. ( NYSE:CAH ) insiders ditched their stock over the past year, which may be of interest to...

Description: Healthcare distributor and services company Cardinal Health (NYSE:CAH) will be announcing earnings results this Thursday before the bell. Here’s what you need to know.

Description: Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Cardinal (CAH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.

Description: The U.S. Cell and Gene Therapy Third-Party Logistics (3PL) Market is anticipated to surge from US$ 2.61 billion in 2024 to US$ 5.88 billion by 2033, maintaining a CAGR of 9.46% from 2025 to 2033. Key growth drivers include increased therapy adoption, specialized logistics needs, and expanding biopharmaceutical collaborations. Regulatory demands, cold chain technology adoption, and challenges such as logistics costs and workforce expertise underscore the market's evolution. States like California

Description: Trying to decide whether to hold, buy, or walk away from Cardinal Health stock? You’re not alone, and for good reason. After all, the company’s shares have defied gravity lately, boasting a one-year surge of 48.1% and a remarkable 301.6% gain over the past five years. Even this year alone, Cardinal Health is already up by 37.2%. Clearly, something more than luck is at play here. If you’ve been tracking recent moves, you’ve probably noticed the healthy 3.5% gain in the past week, capping off a...

Description: In the closing of the recent trading day, Cardinal Health (CAH) stood at $161.89, denoting a +1.72% move from the preceding trading day.

Description: CAH's Pharmaceutical and Specialty units are expected to have fueled double-digit revenue growth in Q1 FY26 despite tariff and cost headwinds.

Description: Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

Description: Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Radiopharmaceutical CDMO Market size & share revenue was valued at approximately USD 2.95 Billion in 2024 and is expected to reach USD 3.1 Billion in 2025 and is expected to reach around USD 7.2 Billion by 2034, at a CAGR of 9.3% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are NorthStar Medical Radioiso

Description: Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Description: [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Aspirin Market size & share revenue was valued at approximately USD 2.52 Billion in 2024 and is expected to reach USD 2.60 Billion in 2025 and is expected to reach around USD 3.40 Billion by 2034, at a CAGR of 3.1% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Bayer AG, Suzhou Kuacai Information Techn

Description: Cardinal Health shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: Earlier this week, Cycle Pharmaceuticals announced the launch of PHYRAGO, a new oncology therapy for leukemia, developed with Handa Therapeutics and made exclusively available in the US through Onco360® and a specialty distribution network that includes McKesson. This collaboration provides McKesson with a valuable commercial opportunity as an exclusive distributor for a newly introduced specialty oncology product in high-need therapeutic areas. We'll explore how McKesson's participation in...

Description: CVS Pharmacy completes the Rite Aid deal, adding 63 stores, 626 pharmacies and nine million patients to its national care network.